Overview
CHDI Management provides administrative, management, and contracting services to CHDI Foundation and other non-profit organizations dedicated to Huntington’s disease (HD) research. It supports rapid discovery and development of HD therapies by handling operations so researchers can focus on science. The company’s work is service-based, not a product; its staff and offices enable global collaboration with academic and industry scientists. CHDI Management differentiates itself by its exclusive focus on Huntington’s disease and its role as the coordinating, nonprofit-backed management arm for HD research initiatives. Its goal is to increase understanding of HD and hasten the development of therapies to delay or slow the disease.
Work here?Claim your company
Simplify's take
What believers are saying
- Prilenia’s May 2026 placebo-data donation expands CHDI’s trial-analytics moat and publication pipeline.
- CHDI won an October 22, 2026 trauma grant, showing funding reach beyond Huntington’s disease.
- Evotec extended its CHDI collaboration in 2026, confirming strategic continuity after twenty years.
What critics are saying
- A 2026 Massachusetts lawsuit names CHDI Foundation, forcing legal spend and management distraction.
- Single-disease dependence on Huntington’s disease creates existential concentration risk if one program fails.
- Evotec remains a critical external engine; disruption there would slow discovery and candidate progression.
What makes CHDI Management unique
- CHDI Management runs CHDI Foundation’s virtual Huntington’s disease research engine, not a traditional lab.
- Its 20-year Evotec alliance gives deep outsourced discovery capacity across biology, chemistry, and biomarkers.
- CHDI controls Enroll-HD and placebo datasets, strengthening trial design and external comparator work.
Help us improve and share your feedback! Did you find this helpful?